profit from every $100 of sales.
$0$100
Cosmos Health
$3.24+4.05% today
-70.3% in 1 year
1-year low $2.581-year high $10.91
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cosmos Health sold, what it kept, and what it did with the cash.
Sales went from $50.3 million in 2022 to $65.3 million in 2025, with -$19.1 million of profit last year.
SalesProfit
Cosmos Health vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cosmos Health | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Cosmos Health's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 50 | 53 | 54 | 65 | |
| 6 | 4 | 4 | 8 | |
| -7 | -22 | -15 | -17 | |
| -9 | -17 | -14 | -15 | |
| -14 | -19 | -16 | -19 | |
| -33.16 | -2.15 | -1.17 | -0.63 | |
| 11.8% | 8.1% | 7.9% | 12.1% | |
| -14.8% | -40.9% | -28.0% | -25.3% | |
| -27.5% | -34.7% | -29.7% | -29.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 68 | 66 | 54 | 65 |
| Cash | 21 | 4 | 0 | 1 |
| Total debt | 12 | 12 | 12 | 20 |
| Total liabilities | 28 | 30 | 30 | 47 |
| 40 | 36 | 25 | 18 | |
| 2 | 12 | 19 | 30 | |
| -13.9% | -28.8% | -33.0% | -34.0% | |
| -34.9% | -51.4% | -66.0% | -103.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -15 | -16 | -8 | -8 | |
| 0 | 9 | 1 | 0 | |
| -15 | -25 | -9 | -9 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | – | |
| 0 | 1 | 2 | 2 |
Valuation
- –
- 40.5×
- –
- 0.5×
- 0.2×
- –
- –
- -52.8%
- -117.4%
- 0.0%
Profitability
- 12.1%
- -25.3%
- -29.3%
- -23.2%
- -40.4%
- -40.1%
- -81.7%
- -29.2%
- -60.8%
- 0.8%
Growth
- +9.0%
- –
- −4.5%
- –
- +160.6%
Financial health
- –
- 0.59
- 16.5%
- -6.8×
- 1.00
- 0.85
- 1.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 946
Bottom 11%of 871
Bottom 42%of 867
Bottom 1%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 20, 2026 | -0.33 | -0.01 | −3,200.0% |
| Nov 14, 2025 | -0.17 | -0.01 | −1,600.0% |
| Aug 18, 2025 | -0.06 | 0.01 | −700.0% |
| May 15, 2025 | 0.01 | -0.03 | +133.3% |
| Apr 15, 2025 | -0.08 | -0.09 | +11.1% |
| Nov 14, 2024 | -0.45 | -0.11 | −309.1% |
| Aug 20, 2024 | -0.04 | -0.14 | +71.4% |
| Aug 6, 2024 | 0.10 | -0.20 | +150.0% |
News
Lucid Recalled 4,400 Gravity SUVs, Delayed the Cosmos, and Is "Buying Time." Here's How Many Shares It Needs to Sell to Survive 2027.Yahoo Finance · Nov 11, 2026Lucid Has Delayed the Cosmos SUV Again. Another Dilutive Raise May Be Coming.Yahoo Finance · Sep 25, 2026Lucid Delayed Its Cosmos SUV. Time to Panic?Yahoo Finance · Sep 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
9No pass
Benjamin Graham
57No pass
Philip Fisher
20No pass
Peter Lynch
38No pass
Joel Greenblatt
0No pass
Charlie Munger
9No pass
Terry Smith
10No pass
Questions about Cosmos Health
Is Cosmos Health a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cosmos Health AI analysis
What does Cosmos Health do?
Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It is in Drug Manufacturers - Specialty & Generic.
Does Cosmos Health pay a dividend?
No. Cosmos Health does not pay a dividend at the moment.
Is Cosmos Health stock halal?
No. Cosmos Health does not pass our halal screen: its debt is 123% of its market value, at or above the 33% limit. How we check
How has Cosmos Health stock done over the past year?
Down 70.3% over the past twelve months, to $3.24. It traded between $2.58 and $10.91 and is 70.3% below its high.
Who are Cosmos Health's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Cosmos Health's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.